Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STC3141 Continuous Infusion in Severe COVID-19 Pneumonia (Phase 2a)
2021-000399-12Phase 2Completed
- Sponsor
- Grand Medical Group AG
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in coronavirus pneumonia comparing STC3141 continuous infusion with Control / standard of care (2 arms). Primary endpoint: Safety (adverse events up to Day 30). Started Mar 2021; status: completed.
02
Drugs
STC3141
03
Conditions
coronavirus pneumonia
Beyond the preview
Go deeper on 2021-000399-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000399-12.